Hepatitis C treatment of patients with bipolar disorder: A case series

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 8, Issue 6, 2006, Pages 361-366

  Rifai, Muhamad Aly ^a,b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CITALOPRAM; CLONAZEPAM; LAMOTRIGINE; LEVOTHYROXINE; LITHIUM CARBONATE; PAROXETINE; PEGINTERFERON; QUETIAPINE; RIBAVIRIN; RISPERIDONE; SERTRALINE; TRAZODONE; VALPROATE SEMISODIUM; VALPROIC ACID;

ADULT; ARTICLE; BIPOLAR I DISORDER; CLINICAL ARTICLE; CONSENSUS; CONSULTATION; DEPRESSION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEPATITIS C; HUMAN; INTRAVENOUS DRUG ABUSE; MALE; MEDICAL DECISION MAKING; MONOTHERAPY; PATIENT COMPLIANCE; SUBSTANCE ABUSE; TREATMENT OUTCOME; TREATMENT REFUSAL;

EID: 33845720312     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/PCC.v08n0607     Document Type: Article

References (42)

1. Strader D, Wright T, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-1171
2. Rifai MA, Bozorg B, Rosenstein DL. Interferon for hepatitis C patients with psychiatric disorders. Am J Psychiatry 2004;161:2331-2332
3. Poynard T, Yuen M-F, Ratziu V, et al. Viral hepatitis C. Lancet 2003;362:2095-2100
4. Kraus MR, Schafer A, Faller H, et al. Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. J Clin Psychiatry 2003;64:708-714
5. Yovtcheva SP, Rifai MA, Moles JK, et al. Psychiatric comorbidity among hepatitis C-positive patients. Psychosomatics 2001;42:411-415
6. Rifai MA, Moles JK, Van Der Linden BJ. The prevalence of psychiatric disorders in patients with chronic hepatitis C. Psychosomatics 2003;44:142-143
7. el-Serag HB, Kunik M, Richardson P, et al. Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology 2002;123:476-482
8. Dinwiddie SH, Shicker L, Newman T. Prevalence of hepatitis C among psychiatric patients in the public sector. Am J Psychiatry 2003;160:172-174
9. Osher FC, Goldberg RW, McNary SW, et al. Blood-borne infections and persons with mental illness: substance abuse and the transmission of hepatitis C among persons with severe mental illness. Psychiatr Serv 2003;54:842-847
10. Loftis JM, Hauser P. The phenomenology and treatment of interferon-induced depression. J Affect Disord 2004;82:175-190
11. Goldsmith RJ, Mindrum G, Myaing M. Psychiatric assessment of patients with hepatitis C virus before initiating interferon treatment. Psychiatr Ann 2003;33:369-376
12. Onyike CU, Bonner JO, Lyketsos CG, et al. Mania during treatment of chronic hepatitis C with pegylated interferon and ribavirin. Am J Psychiatry 2004;161:429-435
13. Carpiniello B, Orru MG, Baita A, et al. Mania induced by withdrawal of treatment with interferon alfa. Arch Gen Psychiatry 1998;55:88-89
14. Rossi A, Renzetti D, D'Albenzio L, et al. Case of mania induced by withdrawal of interferon in a patient affected by bipolar disorder. Psychiatry Clin Neurosci 2002;56:647-648
15. Constant A, Castera L, Dantzer R, et al. Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms. J Clin Psychiatry 2005;66:1050-1057
16. Rifai MA. Hepatitis C patients with psychiatric illness: the forgotten [electronic letter]. Ann Intern Med Nov 9, 2004
17. Zickmund S, Ho EY, Masuda M, et al. "They treated me like a leper": stigmatization and the quality of life of patients with hepatitis C. J Gen Intern Med 2003;18:835-844
18. Schafer M, Boetsch T, Laakmann G. Psychosis in a methadone-substituted patient during interferon-alpha treatment of hepatitis C. Addiction 2000;95:1101-1104
19. Thome J, Knopf U. Acute psychosis after injection of pegylated interferon alpha-2a. Eur Psychiatry 2003;18:142-143
20. Garcia-Pares G, Domenech C, Gil M. Psychosis induced by interferon-alpha. Psychosomatics 2002;43:428-429
21. D'Innella P, Zaccala G, Terazzi M, et al. Psychotic disorders induced by interferon alfa. Recenti Prog Med 2002;93:367-369
22. Kornischka J, Burtscheidt W, Gaebel W. Interferon-induced paranoid psychosis: review of the literature and case report. Nervenarzt 2002;73:463-467
23. Stransky J, Skrivankova J. Serious side-effects of interferon alfa and ribavirin combination therapy in patients with chronic hepatitis C. Vnitr Lek 2002;48:56-59
24. Sabouni D, Rifai MA, Moles JK, et al. Hepatitis C treatment eligibility and outcomes in patients with psychiatric illness. Am J Gastroenterol 2005;100:S117-S118
25. Rifai MA, Moles JK, Short DD. Hepatitis C treatment eligibility and outcomes among patients with psychiatric illness. Psychiatr Serv 2006;57:570-572
26. Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003;37:443-451
27. Dieperink E, Ho SB, Thuras P, et al. A prospective study of neuropsychiatric symptoms associated with interferon-α-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 2003;44:104-112
28. Hauser P, Khosla J, Aurora H, et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 2002;7:942-947
29. Maddock C, Baita A, Orru MG, et al. Psychopharmacological treatment of depression, anxiety, irritability and insomnia in patients receiving interferon-alpha: a prospective case series and a discussion of biological mechanisms. J Psychopharmacol 2004;18:41-46
30. el-Serag HB, Davila JA, Petersen NJ, et al. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003;139:817-823
31. Sylvestre DL, Loftis JM, Hauser P, et al. Co-occurring hepatitis C, substance use, and psychiatric illness: treatment issues and developing integrated models of care. J Urban Health 2004;81:719-734
32. Strader D. Understudied populations with hepatitis C. Hepatology 2002;36:S226-S236
33. Rifai MA, Rosenstein DL. Hepatitis C and psychiatry. Focus 2005;3:194-202
34. Schaefer M, Heinz A, Backmund M. Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules? Addiction 2004;99:1167-1175
35. National Institutes of Health Consensus Development Conference statement: management of hepatitis C: 2002. Hepatology 2002;36:S3-S20
36. Felker BL, Sloan KL, Dominitz JA, et al. The safety of valproic acid use for patients with hepatitis C infection. Am J Psychiatry 2003;160:174-178
37. Kraus MR, Schafer A, Scheurlen M. Paroxetine for the prevention of depression induced by interferon alfa. N Engl J Med 2001;345:375-376
38. Kraus MR, Schafer A, Faller H, et al. Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. Aliment Pharmacol Ther 2002;16:1091-1099
39. Loftis JM, Hauser P. Safety of the treatment of interferon-alpha-induced depression. Psychosomatics 2003;44:524-526
40. Weinrieb RM, Auriacombe M, Lynch KG, et al. A critical review of selective serotonin reuptake inhibitor-associated bleeding: balancing the risk of treating hepatitis C-infected patients. J Clin Psychiatry 2003;64:1502-1510
41. Schafer M, Schmidt F, Grunze H, et al. Interferon alpha-associated agranulocytosis during clozapine treatment: case report and status of current knowledge. Nervenarzt 2001;72:872-875
42. Sene D, Limal N, Cacoub P. Hepatitis C virus-associated extrahepatic manifestations: a review. Metab Brain Dis 2004;19:357-381